Nvax to Receive up to $388 Million Funding from CEPI CASE STUDY

1. Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing

-Funds clinical development of NVX-CoV2373 through Phase 2
-Supports rapid scale-up of vaccine manufacturing
-Allows for increased production of Matrix-M adjuvant
-Reserves global large-scale manufacturing capacity

A Phase 1/2 clinical trial with the Phase I portion starting this month in Australia and the Phase 2 portion conducted in multiple countries following successful Phase 1 top-line results that are expected in July.

ir.novavax.com/news-releases/news-release-details/novavax-receive-388-million-funding-cepi-covid-19-vaccine

2. Novavax Reports First Quarter 2020 Financial Results
-CEPI increases investment up to $388 million for NVX‑CoV2373 vaccine development & manufacturing
-NVX‑CoV2373 Phase I trial initiating in May with preliminary results in July
-NanoFlu recently achieved all primary endpoints in pivotal Phase 3 clinical trial

ir.novavax.com/news-releases/news-release-details/novavax-reports-first-quarter-2020-financial-results